Q1 EPS Estimate for Aptevo Therapeutics Reduced by Analyst
Aptevo Therapeutics Inc. (NASDAQ:APVO – Free Report) – Investment analysts at Roth Capital cut their Q1 2025 earnings per share (EPS) estimates for shares of Aptevo Therapeutics in a research note issued on Monday, February 17th. Roth Capital analyst J. Aschoff now anticipates that the biotechnology company will post earnings of ($4.21) per share for […]
